Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
- Conditions
- Ovarian Cancer
- Registration Number
- NCT06572735
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria:<br><br> - Age = 70 years<br><br> - Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO<br> stage III or IV)<br><br> - PARP inhibitors -naive patient who need to initiate maintenance treatment with PARP<br> inhibitors for the first time (according the the marketing authorization)<br><br> - Patient with a life expectancy of more then 3 months<br><br> - Informed patient which does not oppose to participate to the study<br><br>Exclusion Criteria:<br><br> - Prior treatment with PARP inhibitors<br><br> - Patient incapable to take oral tablets/capsules<br><br> - Participation in a drug trial that does not authorize concurrent participation in<br> another trials<br><br> - Person unable to attend scheduled examinations/appointments as part of routine care<br> for geographical, social or psychological reasons<br><br> - Concomitant cancer or f cancer history (other than those included in the inclusion<br> criteria) treated and considered cured for less than 2 years. However, patients with<br> the following pathologies are eligible:<br><br> - Basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma<br><br> - Stage 1B or less cervical carcinoma<br><br> - Non-invasive superficial bladder cancer
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relative dose intensity of the PARP inhibitors treatment
- Secondary Outcome Measures
Name Time Method